In this interview:
- Belagenpumatucel-Ltherapeutic tumor cell vaccine: OS data (Giaccone G.)
- Clinical activity, safety and biomarkers of PD-L1 blockade (Soria JC)
- Update on 2nd generation ALK inhibitors
For more information:
Abstracts: Presidential Sessions / Lung Cancer – Metastatic and Localised/Systemic
- Abstract: # 2. Authors and title: Giaccone G, Bazhenova L, Nemunaitis J, Juhasz E, Ramlau R, Van den Heuvel MM, Lal R, Dunlop DJ, Carrier E, Fakhrai H. LATE BREAKING ABSTRACT: A phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer (NSCLC) [Abstract Link]
- Abstract: # 3408
Authors and title: Soria JC, Cruz C, Bahleda R, Delord JP, Horn L, Herbst RS, Spigel D, Mokatrin A, Fine G, Gettinger S. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): Additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1) [Abstract Link]
This interview is produced in collaboration with
 |  |
Copyright ? 2012 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.
